Comparison between Beta Drugs IPO and Omfurn India IPO.
Beta Drugs IPO is a SME Fixed Price IPO proposed to list at NSE SME while Omfurn India IPO is a SME Fixed Price proposed to list at NSE SME.
| Beta Drugs IPO | Omfurn India IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Pantomath Capital Advisors Pvt.Ltd. | Sarthi Capital Advisors Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Pantomath Stock Brokers Pvt.Ltd. | Choice Equity Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Beta Drugs IPO is up to ₹18.41 Cr whereas the issue size of the Omfurn India IPO is up to ₹3.95 Cr. The final issue price of Beta Drugs IPO is ₹85.00 per share and of Omfurn India IPO is ₹23.00 per share.
| Beta Drugs IPO | Omfurn India IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Final) | ₹85.00 per share | ₹23.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Market Lot Size | 1600 shares | 6000 shares |
| Fresh Issue Size | 21,66,400 shares | 17,16,000 shares |
| Fresh Issue Size (Amount) | up to ₹18.41 Cr | up to ₹3.95 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 21,66,400 shares | 17,16,000 shares |
| Issue Size Total (Amount) | up to ₹18.41 Cr | up to ₹3.95 Cr |
Beta Drugs IPO opens on Sep 29, 2017, while Omfurn India IPO opens on Sep 29, 2017. The closing date of Beta Drugs IPO and Omfurn India IPO is Oct 04, 2017, and Oct 05, 2017, respectively.
| Beta Drugs IPO | Omfurn India IPO | |
|---|---|---|
| Issue Open | Sep 29, 2017 | Sep 29, 2017 |
| Issue Close | Oct 04, 2017 | Oct 05, 2017 |
| Basis Of Allotment (Tentative) | Oct 10, 2017 | |
| Listing date (Tentative) | Oct 12, 2017 | Oct 13, 2017 |
Beta Drugs IPO P/E ratio is , as compared to Omfurn India IPO P/E ratio of .
| Beta Drugs IPO | Omfurn India IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Standalone)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 93.78% | 100% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 68.89% | 73.40% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹73.52 Cr. | ₹15.67 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Beta Drugs IPO Retail Individual Investors (RII) are offered 10,83,200 shares while in Omfurn India IPO retail investors are offered 10,83,200 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Beta Drugs IPO and 0 shares in Omfurn India IPO.
| Beta Drugs IPO | Omfurn India IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 1,29,600 shares | 96,000 shares |
| QIB | 0 shares | 0 shares |
| NII | 10,83,200 shares | 8,58,000 shares |
| RII | 10,83,200 shares | 8,58,000 shares |
| Employee | 0 shares | 0 shares |
| Total | 21,66,400 shares | 17,16,000 shares |
Beta Drugs IPO subscribed 18.97x in total, whereas Omfurn India IPO subscribed 1.35x.
| Beta Drugs IPO | Omfurn India IPO | |
|---|---|---|
| NII (times) | 29.93x | 0.99x |
| RII (times) | 8.00x | 1.71x |
| Total (times) | 18.97x | 1.35x |
